Thankfully, the FSRH have recently produced guidance on this subject
1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
If a patient finds that a specific dosage or administration method works better for their lifestyle, our providers are there to listen and adjust the plan accordingly
Hold the syringe with the index finger like a pencil or dart
Based on current research, its not yet clear if Wegovy or Ozempic passes into human breast milk, and theres no data on the effects on the breastfed baby or the womans milk production, according to the prescribing information
Monitoring Report: GLP-1 RA Prescribing Trends September 2024 Data
